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infarctions, have also been reported for re-
combinant factor VIIa.3 The relative risks
of these two biologic agents are unknown;
there are no prospective comparative data
available to make such a determination.
The cumulative clinical anecdotal data for
recombinant factor VIIa are from a much
briefer span than those for FEIBA.
Case reports can at times be important for
recognition of new diseases and during
postlicensing surveillance for adverse events.
Recently, a report has demonstrated that the
combination of recombinant factor VIIa and
FEIBA may, if anything, be additive without
increasing adverse responses.4,5
I caution the authors that conclusions
presented with inadequate data may well
lead readers to incorrect interpretations of
the events described.
Louis M. Aledort, MD
The Mary Weinfeld Professor of Clinical
Research in Hemophilia
Mount Sinai School of Medicine
New York, NY 10029
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A few critical aspects—and Achilles
heels— of tissue engineering
approaches to restore injured
myocardium
To the Editor:
We enjoyed reading Osawa and col-
leagues’ article about histologic changes of
biomaterials used to repair ventricular heart
defects in small animals1 as published in
this Journal and also have followed this
group’s work elsewhere.2 Our own review
on the current literature in this area has
spawned many questions and suggestions
for future study designs.
Most published studies do not present
clinically applicable, reparative options.
We believe that a critical analysis of these
studies with respect to geometry, physiol-
ogy, and inflammatory and immunologic
responsiveness of myocardium will help
identify flaws in current study designs and
also help define standardized quality crite-
ria to guide future attempts to manufacture
implantable myocardium.
Few studies, for instance, have reliably
and convincingly proved enhancement of
cardiac function after induction of myocar-
dial injury relative to control values. We
frequently see distorting scaffolds “sitting”
on the heart, or replacing previously beat-
ing muscle, and identify in most of the
cases significant foreign-body reaction and
reactive neovascularization3 interpreted as
angiogenesis. Frequently the immunologic
response to the implanted scaffold and the
inoculated cells is neglected, even when
species barriers are crossed. Furthermore,
many study designs fail to adhere to well-
described “hard problems” in the develop-
ment of bioartificial myocardium:
1. With respect to cardiac geometry, the
ventricular muscle constitutes a com-
plex helical structure.4 Symmetric
and isotropic matrices would pro-
mote scarring and aneurysm forma-
tion. The issues of asymmetry and
anisotropy of the heart have never
been addressed.
2. With respect to cardiac hemodynam-
ics, the modified law of Laplace for
the heart* defines circumferential
wall stress values that would not be
tolerated by most of the described
matrices. Very likely these matrices
would decompose, leading to severe
hemorrhage, or would form aneu-
rysms.
3. With respect to microscopic struc-
ture, we are unaware of approaches
that involve both including nerves
(conductive microstructures) and
preformed chaotic and plastic micro-
channnels simultaneously.
4. With respect to issues of storage,
conservation, and scale, an infant or
child with congenital defects will
*CWS  Pb/h  (1  b2/2a2  h/2b  h/8a2),
where: CWS is circumferential wall stress (in dyne/
cm2  103), P is left ventricular pressure (in dyne/
cm2), a and b are major and minor semiaxes, re-
spectively (in cm) and h is left ventricular wall
thickness (in cm).
Figure 1. Triple staining of carboxyfluorescein diacetate succinimidyl ester–labeled
cells in 3-dimensional scaffold consisting of collagen type 1. Nuclei stain blue. Red
“halo” marks myocytes (MF 20 stain). Here, cluster of cells aligns along fibers (longitu-
dinal structures at left encompassing the cells) of collagen network.
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most probably need a graft different
from one destined to replace failing
myocardium in a 75-year-old patient.
5. With respect to the cells, Wagers and
associates5 have demonstrated that
bone marrow stem cells have little
developmental plasticity. Most of the
tissue engineering approaches with
bone marrow stem cells use whole
bone marrow, rather than specific
subpopulations of it, and they fre-
quently lack identification of the in-
oculated cells because of missing la-
beling and reliable colocalization
studies. What are we implanting?
What happens to each particular cell
population, and to what extent do
these cells transdifferentiate into car-
diomyocytes? Studies with myo-
blasts do no better. Reliability and
interpretability of the results would
be significantly enhanced if cell la-
beling and tracking methods would
be used routinely. Some worth men-
tioning are the green fluorescent pro-
tein or carboxyfluorescein diacetate
succinimidyl ester methods, the
membrane fluorescent intercalated
dye pkh26-gl method, and colocal-
ization or confocal studies to identify
cell identity, location, differentiation
status and host immune response
(Figure 1).
The commentary of this group will cer-
tainly initiate fruitful discussion on basic
requirements for future scientific ap-
proaches to restoring injured myocardium.
Theo Kofidis, MD
Leora B. Balsam, MD
Robert C. Robbins, MD
Cardiothoracic Surgery/Falk Research Center
Stanford University Medical School
Stanford, CA 94305
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Reply to the Editor:
The letter of Kofidis and colleagues from
Stanford University highlights several key
issues that face regenerative medicine as it
applies to the heart. Their insightful per-
spective will help spawn the critical discus-
sion that is required to fulfill the promise of
restoring cardiac structure and function af-
ter cardiac injury. Although we agree that
engineered biomaterial cell-seeded patches
and cellular transplantation are developing,
less than a decade ago heart regeneration
was considered science fiction. We hope
that this discussion will generate more di-
rected research in this emerging discipline.
With respect to cardiac geometry, living
ventricular muscle constitutes a complex
helical structure. It will be ideal to repair
myocardial scar tissue or ventricular de-
fects with asymmetric and anisotropic mus-
cle tissue. However, scar tissue at site of
reconstruction of ventricular aneurysm and
synthetic material used for repair of con-
genital defects is not helical and lacks con-
tractility and growth potential. An autolo-
gous cell-seeded conduit grows with the
child1 when used during correction of con-
genital defects and may reduce the need for
reoperation. Similarly, in large ventricular
aneurysms in which resection needs to be
complemented with a patch, autologous
cell-seeded biomaterials2 may be prefera-
ble to the static materials currently used,
such as pericardium, polytetrafluoroethyl-
ene, and Dacron polyester fabric.
Tissue engineering with cell-seeded
biodegradable materials is a novel technol-
ogy that allows the growth of muscle cells
in three dimensions to regenerate injured
muscle. The biodegradable material does
not repair injured heart segments; rather,
the biomaterial gradually degrades, and it
is the cells in the biomaterial that secrete
extracellular matrix proteins, stimulate an-
giogenesis, and form tissue resembling
myocardial tissue.3,4 The resulting tissue is
fed by neovasculature and consists of mus-
cle as well as a complex matrix that inter-
digitates with the host myocardium. Al-
though the graft is initially isotropic, it
mediates an increase in elasticity and
strength of the scar tissue, prevents scar
expansion, and halts ventricular dilation.2
In addition, the engineered graft will re-
model in response to ventricular pressure
and stretch. Cellular hyperplasia and hy-
pertrophy will enhance the strength of the
graft as the biomaterial degrades. Impor-
tantly, the new muscle tissue has growth
potential and would reduce the necessity
for reoperation.1,3,5
With respect to cardiac hemodynamics,
early biomaterials were unable to withstand
wall stress of the left ventricle. However,
modification of the biomaterials has in-
creased their strength. We have evaluat-
ed2,4 a composite biomaterial consisting of
a spongy central core made of 50% -cap-
rolactone and 50% L-lactic acid that en-
courages tissue ingrowth. The outer layers
are reinforced with knitted poly-L-lactide
fabric, which provides sufficient strength to
prevent disruption when placed in the left
ventricle. The exciting feature of this new
biomaterial is that the spongy portion,
which supports the initial cell inoculum, is
absorbed within 2 months and the fibrous
portion, which provides the strength, per-
sists for 1 to 2 years. We have shown that
smooth muscle cells seed and survive
within this material in vitro and form mus-
cle tissue in vivo.3 The modified biomate-
rial continued to withstand right ventricular
pressures at 6 months after implantation.5
We also used the cell-engineered graft
(poly-L-lactide fabric with smooth muscle
cells) to repair transmural defects of left
ventricular free wall in adult rat hearts after
myocardial infarction. The graft withstood
left ventricular pressures and prevented
ventricular dilation in this model.2 A sim-
ilar material was used as an autologous
cell-seeded patch in the repair of a congen-
ital defect.1
These promising results will need to be
evaluated in larger animal models that re-
quire thicker and more extensive grafts.
The thicker grafts may be limited by the
extent of tissue ingrowth in vitro and of
neovascularization in vivo. The use of de-
cellularized tissue provides the promise of
a preformed vascular supply. However, the
existing structure of the material will be
quickly dissolved by the remodeling pro-
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